Page last updated: 2024-09-04

torcetrapib and evacetrapib

torcetrapib has been researched along with evacetrapib in 20 studies

Compound Research Comparison

Studies
(torcetrapib)
Trials
(torcetrapib)
Recent Studies (post-2010)
(torcetrapib)
Studies
(evacetrapib)
Trials
(evacetrapib)
Recent Studies (post-2010) (evacetrapib)
2732883752072

Protein Interaction Comparison

ProteinTaxonomytorcetrapib (IC50)evacetrapib (IC50)
Cholesteryl ester transfer proteinHomo sapiens (human)0.11

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's18 (90.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Beyer, TP; Borel, A; Cannady, EA; Cao, G; Cockerham, SL; Escribano, A; Fernandez, MC; Frank, S; Jones, TM; Mantlo, NB; Martin de la Nava, EM; Mateo, AI; Parthasarathy, S; Schmidt, RJ; Stephenson, G; Sweetana, SA; Wang, X; Zhang, Y1
Berta, D; Cremonesi, P; Fuchs, K; Hamprecht, D; Luippold, G; Markert, M; Nar, H; Streicher, R; Trieselmann, T; Volz, A; Wagner, H1
Cao, G; Chang, Y; Chen, D; He, X; Huang, X; Liu, J; Luo, H; Ni, S; Shen, Q; Sun, H; Wang, P; Wen, X; Zhou, H1
Brousseau, M; Honma, W; Iimura, A; Imase, H; Iwaki, Y; Kawanami, T; LaSala, D; Liang, G; Mitani, H; Mogi, M; Nonomura, K; Ohmori, O; Pan, M; Rigel, DF; Umemura, I; Yamada, K; Yasoshima, K; Zhu, G1
Amin, RP; Bao, J; Blaustein, RO; Campeau, LC; Chen, Q; Chen, YH; Cote, J; Duffy, JL; Hartmann, G; Johns, DG; Katipally, R; Leung, D; Lipardi, C; Liu, G; Liu, J; Lu, Z; Metzger, D; Mitra, K; Murphy, BA; Ondeyka, D; Shao, PP; Sinclair, PJ; Sun, W; Tan, L; Tyagarajan, S; Vachal, P; Wang, SP; Wollenberg, GK; Xu, Y; Ye, F; Zhao, K1
Nicholls, SJ1
Fisher, EA; Hewing, B1
Duivenvoorden, R; Fayad, ZA1
Akhlaghi, F; Mohammadpour, AH1
Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L1
deGoma, EM; Rader, DJ1
McCullough, PA; Shin, HJ1
Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA1
Boekholdt, SM; Hovingh, GK; Ray, KK1
Quintão, EC1
Barkas, F; Elisaf, M; Filippatos, TD; Klouras, E1
Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS1
Cao, Y; Hao, D; Yang, Z; Yuan, X; Zhang, L; Zhang, S1
Corsini, A; Macchi, C; Matsuzawa, Y; Ruscica, M; Sirtori, CR; Yamashita, S1
Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M1

Reviews

11 review(s) available for torcetrapib and evacetrapib

ArticleYear
Evacetrapib.
    Current cardiology reports, 2012, Volume: 14, Issue:3

    Topics: Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines

2012
Rationale for cholesteryl ester transfer protein inhibition.
    Current opinion in lipidology, 2012, Volume: 23, Issue:4

    Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Drug Discovery; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2012
Safety of CETP inhibition.
    Current opinion in lipidology, 2012, Volume: 23, Issue:6

    Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Oxazolidinones; Quinolines; Safety; Sulfhydryl Compounds

2012
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides

2013
Future of cholesteryl ester transfer protein inhibitors.
    Annual review of medicine, 2014, Volume: 65

    Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2014
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
    Nephron. Clinical practice, 2014, Volume: 127, Issue:1-4

    Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People

2014
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    European journal of clinical investigation, 2016, Volume: 46, Issue:6

    Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds

2016
Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:8

    Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2016
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
    Circulation. Cardiovascular quality and outcomes, 2017, Volume: 10, Issue:6

    Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome

2017
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Atherosclerosis, 2018, Volume: 278

    Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Lignans; Lipoproteins, HDL; Lipoproteins, VLDL; Oxazolidinones; Probucol; Quinolines; Sulfhydryl Compounds; Triglycerides

2018
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
    Nature communications, 2021, 09-24, Volume: 12, Issue:1

    Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2021

Other Studies

9 other study(ies) available for torcetrapib and evacetrapib

ArticleYear
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, May-01, Volume: 22, Issue:9

    Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dose-Response Relationship, Drug; Drug Design; Humans; Inhibitory Concentration 50; Mice; Naphthyridines; Structure-Activity Relationship

2012
Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Journal of medicinal chemistry, 2014, Nov-13, Volume: 57, Issue:21

    Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Hydroxyquinolines; Macaca fascicularis; Mice, Transgenic; Quinolines; Spiro Compounds; Structure-Activity Relationship

2014
Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
    European journal of medicinal chemistry, 2017, Oct-20, Volume: 139

    Topics: Animals; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Drug Discovery; Esters; Guinea Pigs; Humans; Mice; Mice, Transgenic; Molecular Structure; Structure-Activity Relationship; Triterpenes

2017
Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
    Journal of medicinal chemistry, 2017, 10-26, Volume: 60, Issue:20

    Topics: Aged; Animals; Chick Embryo; Cholesterol Ester Transfer Proteins; Humans; Hypertriglyceridemia; Male; Mesocricetus; Piperidines; Rats; Structure-Activity Relationship

2017
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
    Journal of medicinal chemistry, 2021, 09-23, Volume: 64, Issue:18

    Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Dogs; Humans; Macaca mulatta; Mice, Inbred C57BL; Molecular Structure; Oxazolidinones; Rats, Wistar; Structure-Activity Relationship

2021
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Clinical pharmacokinetics, 2013, Volume: 52, Issue:8

    Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2013
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
    Circulation, 2015, Aug-04, Volume: 132, Issue:5

    Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome

2015
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
    Circulation, 2015, Aug-04, Volume: 132, Issue:5

    Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome

2015
Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
    Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:10

    Topics: Anticholesteremic Agents; Benzodiazepines; Binding Sites; Cholesterol Ester Transfer Proteins; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazolidinones; Protein Binding; Protein Structure, Secondary; Quinolines; Solvents; Thermodynamics

2018